The University of Hyderabad (UoH) has signed an agreement with Krismo Biosciences Private Limited to develop therapies for inflammatory diseases and serious infectious conditions.
“A key focus will be on the design of antibody-based therapies to effectively combat viral infections, including dengue, COVID-19 and influenza, as well as potent toxins produced by harmful bacteria responsible for debilitating conditions like gas gangrene,” Nooruddin Khan, Professor at the School of Life Sciences of UoH, said here in a statement on Saturday.
Published on May 3, 2025